NasdaqGM:RAPTBiotechs
RAPT Therapeutics (RAPT): Evaluating Its Rich Valuation After TD Cowen’s Bullish Initiation and Phase 2 Progress
RAPT Therapeutics (RAPT) has been back on traders’ screens after TD Cowen kicked off coverage with a positive stance, following upbeat Phase 2 data for ozureprubart and fresh FDA clearance for a Phase 2b food allergy trial.
See our latest analysis for RAPT Therapeutics.
That backdrop has helped fuel a sharp re-rating, with the stock delivering a 179.68 percent year to date share price return and a 162 percent one year total shareholder return, even as the five year total shareholder return...